Would Zyprexa have become a best-seller for Eli Lilly if its blood-sugar risks had been fully revealed?
Serious Contradictions in Eli Lilly Zyprexa Data
The New York Times reports that for at least a year Eli Lilly provided information to doctors about the blood-sugar risks of its schizophrenia drug Zyprexa that contradicts data circulated within the company when it first reviewed its clinical trial results.
The original results, according to a February 2000 memo, show that patients on Zyprexa were 3.5x more likely to experience high blood sugar levels as those on a placebo. But doctors were given a very different picture until at least late 2001; that Zyprexa patients were only slightly more likely to suffer high blood sugar.
A November 1999 report shows that 16% of patients taking Zyprexa for a year gained more than 66 pounds; Lilly chose instead to focus on data from a different, smaller group of clinical trials that showed 30% of patients gaining 22 pounds.
The memos were provided to The New York Times by a lawyer in Alaska representing mentally ill patients. Weight gain and high blood sugar are risk factors for diabetes, and whether Zyprexa causes diabetes has been a subject of scientific debate for several years. Lilly says no link has ever been proven.
Zyprexa is by far Lilly’s best-selling product, with $4.2b in 2005 sales; 30% of its overall revenue.</blockquote>
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.